Doris P Molina-Henry

Associate Professor of Research Neurology

Image of Doris P Molina-Henry
Is this your profile? Click to edit

Research Funding

  • The Ante-Amyloid Treatment of Alzheimer's disease (A3) Trial and Alzheimer Plasma EXtension (APEX) Study
    NIH · R01AG095009 · Sep 1, 2025 – Aug 31, 2030 · Role: Co-Principal Investigator
  • Cost and Non-Cost Barriers to Use of Novel AD Therapeutics among Older Adults
    NIH · R61AG089049 · Sep 15, 2024 – Aug 31, 2026 · Role: Co-Principal Investigator

Publications

  • A path to preventing cognitive impairment due to Alzheimer’s disease: initiatives beginning in the USA. Lancet Neurol. 2026 Mar; 25(3):268-278.. View in PubMed
  • The Population Neuroscience-Dementia Syndemics Framework to better understand global sex and gender-based risk in low- and middle-income countries. Nat Aging. 2026 Jan; 6(1):38-55.. View in PubMed
  • Greater adherence to healthful dietary patterns is associated with lower insomnia risk in the Women’s Health Initiative Observational Study. Sleep. 2026 Jan 13; 49(1).. View in PubMed
  • Current evidence of randomized clinical trials on hospice-eligible patients with agitation and dementia: A narrative review. Palliat Support Care. 2025 Nov 27; 23:e209.. View in PubMed
  • Racial and ethnic differences in plasma p-tau217 ratio biomarker eligibility rates in a preclinical AD trial with lecanemab. Alzheimers Dement (Amst). 2025 Jul-Sep; 17(3):e70164.. View in PubMed
  • Financial Incentives to Increase Diversity of Older Participants in a Memory Concerns Registry: A Randomized Clinical Trial. JAMA Health Forum. 2025 Aug 01; 6(8):e252273.. View in PubMed
  • Alzheimer Disease Blood Biomarkers and Cognition Among Individuals With Diabetes and Overweight or Obesity. JAMA Netw Open. 2025 02 03; 8(2):e2458149.. View in PubMed
  • Achieving Inclusion in Pharmacological Clinical Trials for Alzheimer’s Disease. Curr Top Behav Neurosci. 2025; 69:229-242.. View in PubMed
  • Public and participant involvement as a pathway to inclusive dementia research. Alzheimers Dement. 2025 01; 21(1):e14350.. View in PubMed
  • Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer’s disease trial. Alzheimers Dement. 2024 06; 20(6):3827-3838.. View in PubMed
  • Erratum to: Association between Modifiable Risk Factors and Levels of Blood-Based Biomarkers of Alzheimer’s and Related Dementias in the Look AHEAD Cohort. JAR Life. 2024; 13:29.. View in PubMed
  • Association between Modifiable Risk Factors and Levels of Blood-Based Biomarkers of Alzheimer’s and Related Dementias in the Look AHEAD Cohort. JAR Life. 2024; 13:1-21.. View in PubMed
  • Relationship between Plasma P-Tau217 and Amyloid PET in Racial and Ethnic Underrepresented Groups (RE-URG) Compared with Non RE-URG in LEARN and A4. J Prev Alzheimers Dis. 2024; 11(4):831-837.. View in PubMed
  • Longitudinal Phospho-tau217 Predicts Amyloid Positron Emission Tomography in Asymptomatic Alzheimer’s Disease. J Prev Alzheimers Dis. 2024; 11(4):823-830.. View in PubMed
  • Pre-Randomization Predictors of Study Discontinuation in a Preclinical Alzheimer’s Disease Randomized Controlled Trial. J Prev Alzheimers Dis. 2024; 11(4):874-880.. View in PubMed
  • Estimating Socio-Economic Status for Alzheimer’s Disease Trials. J Prev Alzheimers Dis. 2024; 11(5):1418-1425.. View in PubMed
  • Examining the Role of Community Engagement in Enhancing the Participation of Racial and Ethnic Minoritized Communities in Alzheimer’s Disease Clinical Trials; A Rapid Review. J Prev Alzheimers Dis. 2024; 11(6):1647-1672.. View in PubMed
  • Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease. Ann Neurol. 2024 02; 95(2):288-298.. View in PubMed
  • Daytime Sleepiness Is Associated with Lower Cognitive Scores: The Look AHEAD Study. JAR Life. 2023; 12:46-55.. View in PubMed